T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia.

Abstract

Cyclosporin A (CsA) is used to prevent rejection in transplantation and to treat autoimmune and hematologic diseases such as aplastic anemia. However, the tumor growth-promoting effect of CsA remains controversial. We report the case of a 24-year-old man who developed acute lymphoblastic leukemia of precursor-T-cell origin after 75 months of treatment with CsA for aplastic anemia. The surface antigen phenotype of his leukemic cells was CD2+, CD3+, CD5+, CD7+, CD4-, CD8-, CD10-, CD20-, CD34-, CD41-, and CD56-. Southern blot analysis revealed a monoclonal rearrangement of T-cell receptor-Jgamma nongermline fragments in HindIII digestion.

• Authors: Y Hirose, Y Masaki, K Ebata, J Okada, C G Kim, N Ogawa, Y Wano, S Sugai
• Journal: International journal of hematology (Int J Hematol) Vol. 73 Issue 2 Pg. 226-9 (Feb 2001) ISSN: 0925-5710 [Print] Japan
• PMID: 11372736 (Publication Type: Case Reports, Journal Article)

Chemical References

• Receptors, Antigen, T-Cell
• Cyclosporine

Topics

• Adolescent
• Anemia, Aplastic (complications, drug therapy)
• Cell Transformation, Neoplastic (drug effects)
• Clone Cells
• Cyclosporine (administration & dosage, adverse effects)
• Gene Rearrangement
• Humans
• Immunophenotyping
• Leukemia, T-Cell (chemically induced, pathology)
• Male
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (chemically induced, pathology)
• Receptors, Antigen, T-Cell (genetics)